Led · Series B · May 2025

Acclaro Medical builds medical aesthetic devices centered on its UltraClear® 2910 nm cold ablative fiber laser, powered by proprietary 3DIntelliPulse™ technology, and the AuraLux™ system that leverages Cool Pulse™ technology. The UltraClear platform is positioned to treat multiple skin layers with claims of improved safety across all skin types, reduced downtime, and faster healing; the company also markets 3DMIRACL™ and Laser Coring™ skin‑rejuvenation treatments. Acclaro intends to use recent financing to accelerate commercial expansion, advance product development, grow its team, and expand global market reach. The company emphasizes clinical efficacy and broader accessibility for aesthetic providers as core commercial messages. Acclaro was founded in 2018 and frames its roadmap around bringing additional pipeline products to market while scaling adoption of UltraClear and AuraLux. The business announced a material capital infusion in May 2025 to support these plans.

Participated · Series D · Jan 2025

GT Medical Technologies develops GammaTile, an FDA-cleared bioresorbable radiation-emitting implant placed at the time of brain tumor resection to deliver immediate, localized radiation to the surgical bed. The company highlights pivotal ROADS Phase 3 randomized controlled trial results presented at ASCO 2026 showing a 12-month surgical bed recurrence rate of 1.3% with GammaTile versus 15.4% with standard of care and improved survival outcomes. GT recently initiated the BRIDGES randomized controlled trial in newly diagnosed glioblastoma patients and plans to use proceeds from its Series E financing to expand that trial and scale commercial and operational efforts. The company was founded by a team of tumor specialists and announced the Series E from Tempe, Arizona. GT positions GammaTile as eliminating the delay between surgery and postoperative radiation by delivering immediate treatment at the resection site. The firm states the clinical data and new financing support its goal of broader adoption and further clinical development.

Participated · Equity · Nov 2024

TailorMed provides an enterprise platform that manages the full lifecycle of patient support programs to reduce cost barriers and improve medication access and adherence. The company has built the nation’s largest Affordability Network, deployed across more than 800 hospitals, 1,300 clinics, and 650 pharmacies. TailorMed integrates directly with manufacturer assistance programs to automate patient support and streamline stakeholder workflows. Having reached an inflection point in its network evolution, the company is expanding into an end-to-end platform to tackle cost, access, and adherence across the medication continuum. The new financing will fund that expansion and broader efforts to create a seamless flow of data and resources across patients, providers, pharmacies, life sciences, and payers. TailorMed frames this work as addressing affordability at the point a prescription is written or dispensed to prevent delayed or skipped treatments. TailorMed Medical provides a technology platform that automates identification of financially at-risk patients and matches and enrolls them in financial resources such as co-pay assistance, replacement drug programs, government subsidies, community and state resources, disease-specific foundations, and programs addressing living expenses. Its platform is designed to reduce out-of-pocket responsibility for patients, helping to eliminate downstream financial hardship and avoidance of care. For health organizations, TailorMed shifts financial assistance from reactive matching or downstream collections to a proactive, point-of-care approach. The company serves physician practices, specialty clinics and health systems, and in 2021 expanded adoption into pharmacies nationwide. TailorMed said it will use the new funding to further expand its reach across health care with innovative financial solutions. Srulik Dvorsky is CEO and co-founder and the company is based in New York City.

Participated · Debt Financing · Aug 2022

MedMinder offers a touchscreen-enabled, automatic pill dispenser that delivers medications from its integrated pharmacy in pre-organized daily trays for the entire month. The company combines its connected dispenser with convenient pharmacy services, personalized clinical care, and analytics aimed at improving adherence and reducing adverse outcomes for aging patients. Through relationships with health plans, home health agencies, provider organizations, long-term care facilities and advocacy groups, MedMinder supports medication management for thousands of seniors and polypharmacy patients and their caregivers. Founded in 2007, the organization employs over 180 team members and is described as an ultra-high-growth pharmacy care organization. MedMinder says it will use recent additional funding to increase capacity to meet growing demand and to offer its holistic pharmacy services nationally. The company plans to build out virtual care, clinical, and technological capabilities to further enable patients to age at home. MedMinder offers a touch screen–enabled automatic pill dispenser and integrated pharmacy service that delivers medications in pre-organized daily trays for an entire month and unlocks only at the prescribed time. The device monitors medication consumption and enables remote monitoring by caregivers and case managers on behalf of payors, as well as telemedicine connections with physicians. The company says it empowers thousands of patients to live more independently while improving adherence. MedMinder was founded in 2007 and is described in the announcement as an ultra-high-growth digital healthcare company. It currently employs over 100 team members across Massachusetts and New York. Management is focused on expanding its connected care and telehealth capabilities and scaling operations. MedMinder is a Needham, MA-based provider of a dispensing system designed to simplify medication management and improve adherence. The company offers pill dispensers paired with alert systems to help patients take medications on schedule. Its service model emphasizes surrounding the patient with a support network of family, friends and professional caregivers. Leadership cited in the article includes Eran Shavelsky (Founder and CEO), Brian Bouvier (Chief Pharmacy Officer), Andrew S. Dibner, Ph.D., and Woodie Flowers, Ph.D. No operating metrics or revenue figures were disclosed in the article. In October 2016 the company received an external investment. MedMinder Systems develops a wireless pill dispenser paired with a complementary medication-management service. The device prompts users to take or refill medications using optional pre-programmed visual and/or auditory alerts. Caregivers and family members can receive real-time email or text notifications about dosage activity, access periodic reports, or log in to review user data. The system is positioned to help users maintain independence and improve medication adherence while keeping families informed. The company is based in Needham, MA and its product emphasizes remote monitoring and caregiver visibility. According to SEC filings, MedMinder recently completed an equity financing round, indicating recent outside investor interest.

Participated · Equity · Jun 2022

Corvia Medical develops the Corvia Atrial Shunt, a transcatheter device designed to reduce elevated left atrial pressure in patients with HFpEF or HFmrEF. The shunt is placed via catheter between the left and right atria to allow blood flow from the higher-pressure left atrium to the lower-pressure right atrium. The device was granted Breakthrough Device designation by the FDA in 2019. Corvia says the shunt aims to reduce heart-failure symptoms and events and improve quality of life. The company is led by CEO George Fazio and is based in Tewksbury, MA. Corvia recently raised USD54M to support a confirmatory trial building on data and learnings from the REDUCE LAP-HF II clinical trial. DC Devices develops the proprietary, minimally invasive InterAtrial Shunt Device (IASD) System, the world’s first transcatheter implant intended to treat diastolic heart failure (HFpEF) by reducing elevated left atrial pressure. The IASD is designed to be implanted in the atrial septum via standard interventional cardiology techniques, avoiding open‑heart surgery. The company positions the device to relieve symptoms, improve quality of life, and reduce heart failure hospitalizations. DC Devices says the IASD System is intended to be cost‑effective and is aimed at a roughly $5 billion global market opportunity. Current plans for the new capital focus on completing clinical evaluation of the IASD System. The IASD is an investigational device and is not currently available for commercial distribution. DC Devices develops a proprietary, minimally invasive InterAtrial Shunt Device (IASD) system to treat diastolic heart failure (DHF), also known as HFpEF. The IASD is designed to relieve increased left atrial pressure by placing a permanent implant in the atrial septum. The system enables physicians to perform a controlled trans-catheter treatment without open-heart surgery using standard interventional cardiology techniques. Led by president and CEO George Fazio with co-founder David Celermajer, M.D., the company focuses on structural heart solutions. The company said it will use the financing to accelerate development and ongoing clinical evaluation of its first trans-catheter device for DHF/HFpEF.